Last reviewed · How we verify
SCOPOLAMINE
Scopolamine is a muscarinic antagonist used primarily for motion sickness and as an adjunct in anesthesia. It blocks acetylcholine receptors, reducing nausea and vomiting. Key approved indications include motion sickness and preoperative sedation. Scopolamine is differentiated by its rapid onset and long duration of action. Commercially, it is widely used but lacks recent revenue data. Current research focuses on expanding its use in conditions like bipolar depression and chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | SCOPOLAMINE |
|---|---|
| Also known as | hyoscine |
| Drug class | Anticholinergic [EPC] |
| Target | Muscarinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1979 |
Approved indications
- Motion sickness — any
- Preoperative sedation — any
- Postoperative nausea and vomiting — any
Pipeline indications
- Bipolar depression — Phase 2
- Chronic obstructive pulmonary disease (COPD) — Phase 2
Common side effects
- Dry mouth
- Dizziness
- Somnolence
- Agitation
- Visual Impairment
- Confusion
- Mydriasis
- Pharyngitis
- Drowsiness
- Blurred vision
- Dilation of the pupils
- Headache
Serious adverse events
- Acute angle closure glaucoma
- Acute psychosis
- Disorientation
- Hallucinations
- Paranoia
- Amnesia
- Coordination abnormalities
- Disturbance in attention
- Speech disorder
- Hyperthermia
Drug interactions
- Other anticholinergics
- Central nervous system depressants
- Monoamine oxidase inhibitors (MAOIs)
Key clinical trials
- Valethamate Bromide Versus Hyoscine Butyl Bromide in Reducing Labour Duration Among Primigravida (NA)
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects (PHASE1)
- Representation of Spatiotemporal Information in Human Episodic Memory and Navigation (EARLY_PHASE1)
- Oral Hyoscine vs. Topical EMLA vs. Placebo for Pain Reduction During Hysterosalpingography (NA)
- Evaluation of the Efficacy of the Injection of Botulinum Toxin A vs Scopolamine Patches in the Treatment of Drooling in Children With Cerebral Palsy (PHASE3)
- A Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy Procedures (NA)
- Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP) (PHASE2)
- Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| Composition of Matter |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCOPOLAMINE CI brief — competitive landscape report
- SCOPOLAMINE updates RSS · CI watch RSS